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INTRODUCTION
Oxcarbazepine recently gained a licence in the UK
and USA. The purpose of this article is to review
the pharmacology and therapeutics of oxcarbazepine
for those prescribers unfamiliar with this interesting
new antiepileptic drug1–3. Although only newly li-
censed in the UK and USA, oxcarbazepine has in fact
been in routine clinical use in Denmark and other
countries for up to 10 years, and experience of more
than 200 000 patients years has been gained. Within
the regulatory database, there are detailed records of
around 7000 patients worldwide. This is an unusually
large experience, and oxcarbazepine comes into prac-
tice within the UK with a great deal of background
data concerning its pharmacological and clinical prop-
erties, and a wide range of indications. Indeed, oxcar-
bazepine is already considered a first line therapy in
certain countries for a range of epilepsy indications1.
PHYSICAL AND CHEMICAL
CHARACTERISTICS
Oxcarbazepine is the 10 keto analogue of carba-
mazepine. It is a neutral lipophilic compound, and,
like carbamazepine, very insoluble in water. It is not
clear whether it is as unstable in humid conditions
as is carbamazepine. The antiepileptic action of car-
bamazepine is, like carbamazepine3–7, thought to be
due primarily to blockage of voltage sensitive sodium
channels resulting in stabilization of hyper-excited
neural membranes, inhibition of repetitive neuronal
firing and inhibition of the spread of discharges. It
also increases potassium conductance, reduces glu-
taminergic transmission and modulates calcium chan-
nel function. The rationale behind its original de-
velopment was to use the parent molecule carba-
mazepine as a template, and to produce a drug as
effective as carbamazepine, but with an improved
side-effect profile. A key difference between the two
drugs is that oxcarbazepine unlike carbamazepine is
not metabolized to an epoxide derivative. As the
epoxide is responsible for some of the toxic effects
of carbamazepine, the lack of epoxidation of oxcar-
bazepine is probably one reason for its better side-
effect profile. Its biotransformation is largely by hy-
droxylation, to an active non-toxic 10-monohydroxy
metabolite (MHD: 10,11 dihydro-10-hydroxy-5H-
dibenzol[b,f]azepine-5-carboxamide)8. The pharma-
cological action of the drug is exerted primarily though
this metabolite, and oxcarbazepine is in essence a pro-
drug of MHD.
PHARMACOKINETICS
Absorption and distribution
Oxcarbazepine is absorbed almost completely after
oral ingestion, and this is an advantage over carba-
mazepine. Absorption is not affected by food9. Ox-
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carbazepine is rapidly and almost completely me-
tabolized to the biologically active 10-monohydroxy
metabolite MHD. Following ingestion, there is lit-
tle parent drug circulating in the plasma, although
MHD is widely distributed to brain and other lipid
tissues1–3, 8, 10, 11. The volume of distribution is 0.3–
0.8 l/kg and it is 38% bound to plasma proteins. Foetal
and maternal plasma concentrations of the drug are
similar (as judged by the neonatal and maternal lev-
els in one case) and the plasma: breast milk ratio of
oxcarbazepine is 0.5.
Biotransformation and excretion
Oxcarbazepine is rapidly and extensively metabo-
lized in the liver via a reductive pathway, and less
than 1% of the drug is excreted unchanged in the
urine1–3, 8, 10, 11 (Fig. 1). The primary metabolite MHD
is conjugated to a glucuronide compound. It is not sub-
ject to epoxidation as is the case of carbamazepine.
The biotransformation is rapid and almost complete,
and only trace amounts of oxcarbazepine are found in
the blood. A small amount of a dihydroxy derivative
(DHD) is also formed. Peak serum concentrations of
MHD are reached in 4–6 hours. The plasma half life of
MHD is about 8–10 hours, and is not altered by con-
comitant antiepileptic drug therapy. There is a linear
relationship between dose and serum levels of the drug
and its metabolite in the usual clinical dose ranges.
The drug is largely excreted by the kidneys, 83% as
MHD or its glucuronide, 4–7% as the DHD, and 0.3–
3% as oxcarbazepine. Due to this dependency on renal
excretion, the dose of oxcarbazepine may need to be
reduced in the presence of severe renal impairment12.
Drug interactions
Oxcarbazepine results in only a very low level of hep-
atic cytochrome P450 enzyme induction, and this is
a great advantage over carbamazepine. There is no
auto-induction, and there are fewer interactions of
oxcarbazepine with other drugs than observed with
carbamazepine1–3, 10, 11. Most cytochrome P450 en-
zymes are unaffected by the drug (including CYP1A2,
CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9,
CYP4A11), and thus the common interactions typi-
cal of carbamazepine, for instance, are absent. Ox-
carbazepine therefore does not usually alter the levels
of the other commonly used antiepileptic drugs. Con-
versely, the enzyme-inducing effect of carbamazepine,
phenytoin and phenobarbital can reduce the bioavail-
ability of MHD, and the oxcarbazepine dose may need
to be higher in some patients who are co-medicated
with these drugs13. As oxcarbazepine results in less
liver enzyme induction than carbamazepine, it has
fewer effects on thyroid or sex hormones14, 15. Oxcar-
bazepine has been shown not to induce the metabolism
or interact with other non-epileptic drugs such as
warfarin, cimetidine, erythromycin, verapamil or dex-
tropropoxyphene1–3, 10, 11. The only cytochrome P450
enzymes inhibited by oxcarbazepine are CYP2C19,
CYP3A4 and CYP3A5. As a result, oral contracep-
tive levels may be lower on co-medication with ox-
carbazepine. Due to this potential interaction, women
medicated with oxcarbazepine who require the contra-
ceptive pill should take a high (50 µg) oestrogen for-
mulation, and be warned about the potential hazard to
contraception16, 17. There is insufficient data to make
any statement about its safety in pregnancy, and the
drug should be not be used in pregnant patients.
SIDE-EFFECTS
The side-effect profile of oxcarbazepine is similar in
nature to that of carbamazepine, although the fre-
quency and severity of side-effects have been shown to
be less1, 3, 11, 18, 19. The commonest dose-related side-
effects are fatigue, headache, dizziness and ataxia.
In a comparative monotherapy trial in 235 outpa-
tients with newly diagnosed epilepsy, some side-
effects were reported by 68% receiving oxcarbazepine
and 74% receiving carbamazepine, but the mean num-
ber of side-effects per patient was lower with ox-
carbazepine compared with carbamazepine (2.8 vs.
3.5)18. Other side-effects included nausea and gas-
trointestinal disturbance. Two studies have shown no
impairment of cognitive function after 4–12 months
of therapy with oxcarbazepine20, 21. In the compara-
tive randomized controlled trials in both adults and
children, the side-effect profile of the drug was bet-
ter than with carbamazepine or phenytoin, and ox-
carbazepine scored better on patients’ and physi-
cians’ rating scales than carbamazepine, valproate
or phenytoin1–3, 11. The withdrawal rates from side-
effects in the published monotherapy studies of ox-
carbazepine can be take as a good index of toler-
ability. These were better on oxcarbazepine when
compared to published studies of carbamazepine,
valproate and phenytoin (Table 1). There has been
no published comparison of the tolerability of ox-
carbazepine and newer antiepileptic drugs or slow-
release carbamazepine, which would be of interest
in view of the improved tolerability of the slow re-
lease compared to the standard carbamazepine formu-
lation.
Skin rash is relatively common19 (up to 10% of
all patients) and is the main reason for discontin-
uation of the drug in the comparative monother-
apy studies1–3, 11, 19. The rash is similar to that of
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Fig. 1: The metabolism of oxcarbazepine by a reductive pathway, compared with carbamazepine.
Table 1: Side-effects necessitating withdrawal from published monotherapy comparative trials18, 19, 22, 23.
Adverse event OXC (n = 462) CBZ (n = 100) VPA (n = 121) PHT (n = 240)
18, 19, 22, 23 19 22 18, 23
% (n) % (n) % (n) % (n)
Abnormal vision
Allergy/Rash 3.8% (18) 16% (16) 5.8% (14)
Alopecia 2% (2) 3.3% (4)
Diarrhoea 2% (2)
Dizziness 0.6% (3)
Drowsiness/Fatigue/Sedation 0.6% (3) 3% (3) 0.42% (1)
Gum/Hirsutism 5.8% (15)
Headache
Increased liver parameters
Leucopenia
Nausea 0.2% (1) 1% (1) 1.6% (2)
Pregnancy 1.6% (2)
Others 2.0% (10)a 4% (4)b 1.6% (2)c
Total discontinuations 7.6% (35) 25% (25) 8.3% (10) 12.5% (30)
a Includes one patient on methotrexate with toxic megacolon and reversible bone marrow suppression, one patient with raised intracranial
pressure (an astrocytoma was diagnosed after enrollment), two pregnancies, one suicide attempt, and one report each of abdominal pain,
psychosis, tongue ulceration, and psychic lability. b Includes one report each of abnormal vision, headache, leucopenia, and raised liver
parameters. c Includes one report each of embolism and abdominal pain.
carbamazepine, although cross-reactivity with carba-
mazepine is present in only about 25–30% of cases,
and so oxcarbazepine is a useful drug in patients who
are shown to have carbamazepine hypersensitivity1, 11.
Oxcarbazepine, like carbamazepine, may cause
hyponatraemia presumably due to an antidiuretic
hormone-like effect24, 25. The effect seems to be
greater with oxcarbazepine than carbamazepine, and
about 20% of all patients show a serum sodium level
below 135 mmol/l. The degree of hyponatraemia is
however usually mild and is generally asymptomatic
and not of clinical importance. It is a dose-dependant
effect, and alleviated by dose reduction or water re-
striction. The incidence of marked hyponatraemia (be-
low 125 mmol/l) was only 2.7%, in our study, and was
generally asymptomatic26. There is no need to moni-
tor the sodium levels regularly, unless there are special
risks (e.g. in patients taking diuretics or in the elderly).
ANTIEPILEPTIC EFFECT
Oxcarbazepine was first subjected to clinical trials
in the 1980s1–3, 11, 19 and it was on this basis that
the drug was licensed in Denmark and other coun-
tries. A large number of open clinical trial were pub-
lished, and considerable experience with the drug ob-
tained. A further clinical trial programme was em-
barked upon in the early 1990s, in order to com-
ply with GCP (Good Clinical Practice) guidelines
and to allow the drug to be put forward for licens-
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ing in the USA, UK and more widely in Europe.
This trial programme has now been successfully com-
pleted, and the antiepileptic efficacy of the drug has
been proven beyond question2, 3, 11, 18, 23, 24, 26, 27. Sig-
nificant superiority of oxcarbazepine over placebo
was demonstrated in the add-on trials in adults and
children. In adults, the median reduction in partial
seizure frequency was between 26% (600 mg/day)
and 40% (2400 mg/day), and the number of respon-
ders (>50% reduction in seizure frequency) was also
significantly greater on 2400 mg than 600 mg/day
(50% vs. 27%, respectively). (Barcs et al, submitted
to Epilepsia). Furthermore, oxcarbazepine has been
tested in four randomized double-blind monotherapy
trials, including one short-term study of patients be-
ing evaluated for epilepsy surgery29, one study in
new patients30 and two monotherapy substitution stud-
ies in refractory cases31, 32. All four studies demon-
strated that a high dose of the drug was either su-
perior to placebo or to a low dose29–32. An excel-
lent feature of the trial programme is that compara-
tive data was also obtained comparing oxcarbazepine
to other established antiepileptic drugs (and not just
placebo)18, 19, 22. These trials have shown that oxcar-
bazepine is at least as effective as carbamazepine, val-
proate and phenytoin and superior to placebo, and
had superior tolerability when compared to the other
antiepileptics. Significantly fewer patients treated with
oxcarbazepine necessitated withdrawal due to side-
effects oxcarbazepine as add-on therapy show a linear
dose response relationship.
One key advantage of oxcarbazepine is less en-
zyme induction than many other antiepileptic drugs,
including carbamazepine, leading to fewer drug inter-
actions. If oxcarbazepine is being substituted for car-
bamazepine, care is needed, as de-induction could al-
ter levels of concomitant medication. The only clini-
cally significant interaction for oxcarbazepine is with
the contraceptive pill, and high dose oestrogen con-
traceptives (50 µg) should be used, patients warned
about the risks of drug interaction and the potential
for contraceptive failure discussed. One particular in-
dication for oxcarbazepine is as an alternative to car-
bamazepine in patients who develop a carbamazepine-
induced rash. Studies have shown that there is only
about 25–30% cross-sensitivity19.
The most common chronic effect with oxcar-
bazepine is hyponatraemia, but this is usually mild,
asymptomatic and of no clinical significance. The hy-
ponatraemia is likely to be possibly due to a marked
antidiuretic effect, and the consumption of large fluid
volumes (including large quantities of beer) should be
discouraged. This is of particular relevance to younger
patients. In routine clinical practice, serum sodium
need not be monitored, unless there are special risks
(e.g. in patients taking diuretics or in the elderly).
Anecdotal clinical practice in Denmark suggests
that oxcarbazepine can be substituted for carba-
mazepine rapidly—within one dose—replacing car-
bamazepine with oxcarbazepine in a dosing ratio of
200 mg : 300 mg with no need for titration. It than
phenytoin or carbamazepine18, 19. A therapeutic range
of MHD of 50–125 µmols/l has been suggested. Sim-
ilarly, in children, oxcarbazepine was at least as effec-
tive as phenytoin but had improved tolerability23.
A large retrospective post-marketing study,
analysing 10 years clinical experience with the drug
has been reported in 947 patients. Eighty-two percent
of patients were switched from other AEDs to oxcar-
bazepine (68% from carbamazepine)33. Sixty-three
percent of patients were receiving monotherapy. Ox-
carbazepine significantly reduced seizure frequency
in 32–48% of patients. In another study of switching
patients from carbamazepine to oxcarbazepine, 8% of
patients became seizure free and 32% experienced a
greater than 50% reduction in seizures. Seventy-nine
percent of patients had improved tolerability on oxcar-
bazepine compared to carbamazepine34.
CLINICAL USE IN EPILEPSY
Oxcarbazepine is licensed for use as monotherapy
or adjunctive therapy in patients with partial onset
seizures with or without secondary generalization. In
either situation, its efficacy is excellent, and is at least
equivalent to that of other first line drugs. It has a sig-
nificant effect both in partial and in secondarily gen-
eralized seizures in children and in adults. It is also
somewhat better tolerated than other first line drugs,
and only a small proportion of patients withdraw from
therapy in the large comparative clinical trials. Ox-
carbazepine is likely to be effective in all situations
in which carbamazepine might be used, although its
wider use in generalized epilepsy syndromes is rela-
tively unexplored. Recent randomized controlled stud-
ies of has been shown that oxcarbazepine can be added
to carbamazepine with additive efficacy and accept-
able tolerability; further work is needed to confirm this
interesting observation.
Oxcarbazepine is currently only available as an
oral formulation. It can be introduced more quickly
than carbamazepine, and indeed, the starting dose of
600 mg/day is clinically effective. For all patients
therapeutic levels of oxcarbazepine can be reached
within days of starting treatment. In adults a start-
ing dose of 600 mg/day can be increased weekly in
600 mg increments to a usual maintenance dose of
between 900–1200 mg/day in twice daily dosing in-
tervals. The initial dose in children is 10 mg/kg/day
increasing in 10 mg/kg steps to 30 mg/kg/day. Be-
cause the metabolism of oxcarbazepine is increased by
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enzyme-inducing drugs, patients co-medicated with
phenytoin or phenobarbitone may need somewhat
higher doses of oxcarbazepine than for monotherapy;
to what extent this is clinically important has not been
established, and dosage should be guided by clinical
response. In moderate or severe renal failure, the dose
of oxcarbazepine may need to be lowered.
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